CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Mohammad Pashmforoush |
Dr. Mohammad Pashmforoush |
New Faculty I |
Medical School Loan Repayment Program |
$27,949 |
| Salk Institute for Biological Studies |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$2,134,100 |
| University of California, Los Angeles |
Dr. Dana Leanne Jones |
New Faculty I |
Characterization of mechanisms regulating de-differentiation and the re-acquisition of stem cell identity |
$382,773 |
| University of California, Los Angeles |
Dr. Siavash Kurdistani |
New Faculty I |
Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
| University of California, Santa Cruz |
Dr. Camilla Forsberg |
New Faculty I |
Mechanisms of Stem Cell Fate Decisions |
$2,201,759 |
| University of Southern California |
Dr. Mohammad Pashmforoush |
New Faculty I |
Transcriptional Regulation of Cardiac Pacemaker Cell Progenitors |
$2,816,578 |
| University of California, Berkeley |
Dr. Irina M. Conboy |
New Faculty I |
Identification of hESC-mediated molecular mechanism that positively regulates the regenerative capacity of post-natal tissues |
$2,246,020 |
| University of California, Santa Cruz |
Dr. Bin Chen |
New Faculty I |
Molecular mechanisms of neural stem cell differentiation in the developing brain |
$2,147,592 |
| University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
New Faculty I |
In vitro reprogramming of mouse and human somatic cells to an embryonic state |
$2,229,427 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Douglas Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$621,639 |
| Western University of Health Sciences |
Dr. Douglas W Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$1,401,642 |
| University of California, Davis |
Dr. Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
| University of California, Los Angeles |
Dr. Hanna Mikkola |
New Faculty I |
Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
| City of Hope, Beckman Research Institute |
Dr. Tiziano Barberi |
New Faculty I |
Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy |
$131,840 |
| Scripps Research Institute |
Kristin Baldwin |
New Faculty I |
Generating pluripotent cell lines from neurons. |
$2,786,560 |
| Salk Institute for Biological Studies |
Dr. Lei Wang |
New Faculty I |
Genetic Encoding Novel Amino Acids in Embryonic Stem Cells for Molecular Understanding of Differentiation to Dopamine Neurons |
$2,587,742 |
| Stanford University |
Dr. Anne Brunet |
New Faculty I |
Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,435 |
| University of California, Merced |
Dr Jennifer O Manilay |
New Faculty I |
Enhancing Survival of Embryonic Stem Cell-Derived Grafts by Induction of Immunological Tolerance |
$1,576,389 |
| University of California, Irvine |
Dr. Andrew Putnam |
New Faculty I |
A Novel Engineered Niche to Explore the Vasculogenic Potential of Embryonic Stem Cells |
$395,764 |
| Stanford University |
Dr. Joanna Wysocka PhD |
New Faculty I |
Trithorax and Polycomb methyltransferase complexes in cell fate determination. |
$2,373,903 |
| University of California, San Diego |
Dr. Kentson Lam |
New Faculty I |
Genetic dissection of mesodermal commitment to the hematopoietic fates. |
$2,150,620 |
| University of Southern California |
Dr. Songtao Shi |
New Faculty I |
Oral and Craniofacial Reconstruction Using Mesenchymal Stem Cells |
$3,242,651 |
| Scripps Research Institute |
Dr. Sheng Ding Dr. |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,393,876 |
| Gladstone Institutes, J. David |
Sheng Ding PhD |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,320,101 |
| Stanford University |
Karl Deisseroth |
New Faculty I |
Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny |
$2,424,209 |
| Stanford University |
Dr. Howard Y. Chang |
New Faculty I |
Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
| BioTime, Inc. |
Dr. Michael D West Ph.D. |
Early Translational I |
Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines |
$4,721,706 |
| University of California, Davis |
Dr. Alice F Tarantal |
Early Translational I |
In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
$3,143,392 |
| Salk Institute for Biological Studies |
Dr. Inder M. Verma |
Early Translational I |
Curing Hematological Diseases |
$5,979,252 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Evan Y. Snyder |
Early Translational I |
Developmental Candidates for Cell-Based Therapies for Parkinson’s Disease (PD) |
$5,190,752 |
| Stanford University |
Dr. Jill Helms |
Early Translational I |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
| Jackson Labs |
Pali G. Kaur |
Early Translational I |
Mouse Models for Stem Cell Therapeutic Development |
$3,759,134 |
| Gladstone Institutes, J. David |
Dr. Warner C Greene |
Early Translational I |
Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation |
$1,280,001 |
| Scripps Research Institute |
Dr. Martin Friedlander |
Early Translational I |
Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
| University of California, Los Angeles |
Dr. Gabriel H. Travis |
Early Translational I |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Early Translational I |
Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
| ViaCyte, Inc. |
Dr. Olivia G. Kelly |
Early Translational I |
Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product |
$5,405,397 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
